Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6080-6086

  Furuta, Junichi ^a,b   Nobeyama, Yoshimasa ^a   Umebayashi, Yoshihiro ^b   Otsuka, Fujio ^b   Kikuchi, Kanako ^c   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PEROXIREDOXIN; PEROXIREDOXIN 2; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CPG ISLAND; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; MELANOMA CELL; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CPG ISLANDS; DNA METHYLATION; GENE SILENCING; GENOME, HUMAN; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NUCLEIC ACID HYBRIDIZATION; PEROXIDASES; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL;

EID: 33745728166     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0157     Document Type: Article

References (24)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
3. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005;96:206-11.
4. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
5. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 2005;35:293-301.
6. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
7. Furuta J, Umebayashi Y, Miyamoto K, et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004;95:962-8.
8. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 2004;23:5215-26.
9. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-22.
10. Ushijima T, Morimura K, Hosoya Y, et al. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 1997;94:2284-9.
11. Kaneda A, Takai D, Kaminishi M, Okochi E, Ushijima T. Methylation-sensitive representational difference analysis and its application to cancer research. Ann N Y Acad Sci 2003;983:131-41.
12. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
13. Lagonigro MS, De Cecco L, Carninci P, et al. CTAB-urea method purifies RNA from melanin for cDNA microarray analysis. Pigment Cell Res 2004;17:312-5.
14. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002;99:3740-5.
15. Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 2004;212:203-10.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
17. Hagihara A, Miyamoto K, Furuta J, et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004;23:8705-10.
18. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407-14.
19. Choi MH, Lee IK, Kim GW, et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 2005;435:347-53.
20. Carta F, Demuro PP, Zanini C, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005;15:235-44.
21. Memon AA, Chang JW, Oh BR, Yoo YJ. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev 2005;29:249-55.
22. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781-90.
23. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002;21:1048-61.
24. van Doom R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005;23:3886-96.